At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 315 enrolled
Drug / intervention
Jaktinibdrug
Likely dose
Jaktinib 75mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Adult Patients With Moderate to Severe Alopecia Areata
In Brief
A Phase 3 clinical trial evaluating Jaktinib for Alopecia Areata. Completed, enrolled 315 participants across 1 site.
Detailed Summary
This study (Unique Protocol ID: ZGJAK020) as an extension of the ongoing "Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (Unique Protocol ID:ZGJAK020)" study. After completion of ZGJAK018 study, the study will be directly extend with an "open-label design".
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedFeb 2022
Enrollment StartMar 2022
Primary CompletionJun 2024
TodayJul 2026
First PostedFeb 24, 2022
Enrollment StartMar 25, 2022
Primary CompletionJun 28, 2024
TodayJul 1, 2026
Enrollment to primary: 2.3 yearsPosted 4.4 years ago
Interventions
Jaktinibdrug
75mg BID